Why is pancreatic adenocarcinoma not screened for earlier?

Maroni, Lorenzo; Ravaioli, Matteo; Pinna, Antonio Daniele

doi:10.1080/14737140.2016.1224972

Cited by 3 publications

(2 citation statements)

References 21 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As one of the deadliest types of cancer, PDAC is commonly diagnosed in late stages and is associated with rapid progression and metastasis, resulting in the ASR for 5-year net survival less than 5% [5,6,19,20]. Due to the lack of effective therapy, cure is seldom considered as a treatment outcome while efforts are mainly intended to prolong the survival of PDAC patients.…”

Section: Discussionmentioning

confidence: 99%

Key drug-targeting genes in pancreatic ductal adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal type of cancer. In this study, we undertook a pairwise comparison of gene expression pattern between tumor tissue and its matching adjacent normal tissue for 45 PDAC patients and identified 22 upregulated and 32 downregulated genes. PPI network revealed that fibronectin 1 and serpin peptidase inhibitor B5 were the most interconnected upregulated-nodes. Virtual screening identified bleomycin exhibited reasonably strong binding to both proteins. Effect of bleomycin on cell viability was examined against two PDAC cell lines, AsPC-1 and MIA PaCa-2. AsPC-1 did not respond to bleomycin, however, MIA PaCa-2 responded to bleomycin with an IC 50 of 2.6 μM. This implicates that bleomycin could be repurposed for the treatment of PDAC, especially in combination with other chemotherapy agents. In vivo mouse xenograft studies and patient clinical trials are warranted to understand the functional mechanism of bleomycin towards PDAC and optimize its therapeutic efficacy. Furthermore, we will evaluate the antitumor activity of the other identified drugs in our future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Key drug-targeting genes in pancreatic ductal adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Yet diagnosis can be challenging. [ 1 , 3 , 4 ] Since early symptoms may be nonspecific, vague, and intermittent (eg, weight loss, nonspecific abdominal pain) and often attributed to coexisting disorders or ageing, diagnosis is commonly delayed. [ 1 , 5 – 8 ] In fact, the total diagnostic interval (ie, from onset of symptoms to diagnosis) of pancreatic cancer is longer than the interval of other cancers including other hard-to-suspect cancers.…”

Section: Introductionmentioning

confidence: 99%

What is the relevance of an ambulatory quick diagnosis unit or inpatient admission for the diagnosis of pancreatic cancer? A retrospective study of 1004 patients

et al. 2020

View full text Add to dashboard Cite

Quick diagnosis units (QDU) have become an alternative hospital-based ambulatory medicine strategy to inpatient hospitalization for potentially serious illnesses in Spain. Whether diagnosis of pancreatic cancer is better accomplished by an ambulatory or inpatient approach is unknown. The main objective of this retrospective study was to examine and compare the diagnostic effectiveness of a QDU or inpatient setting in patients with pancreatic cancer. Patients with a diagnosis of pancreatic adenocarcinoma who had been referred to a university, tertiary hospital-based QDU or hospitalized between 2005 and 2018 were eligible. Presenting symptoms and signs, risk and prognostic factors, and time to diagnosis were compared. The costs incurred during the diagnostic assessment were analyzed with a microcosting method. A total of 1004 patients (508 QDU patients and 496 inpatients) were eligible. Admitted patients were more likely than QDU patients to have weight loss, asthenia, anorexia, abdominal pain, jaundice, and palpable hepatomegaly. Time to diagnosis of inpatients was similar to that of QDU patients (4.1 [0.8 vs 4.3 [0.6] days; P = .163). Inpatients were more likely than QDU patients to have a tumor on the head of the pancreas, a tumor size >2 cm, a more advanced nodal stage, and a poorer histological differentiation. No differences were observed in the proportion of metastatic and locally advanced disease and surgical resections. Microcosting revealed a cost of €347.76 (48.69) per QDU patient and €634.36 (80.56) per inpatient ( P < .001). Diagnosis of pancreatic cancer is similarly achieved by an inpatient or QDU clinical approach, but the latter seems to be cost-effective. Because the high costs of hospitalization, an ambulatory diagnostic assessment may be preferable in these patients.

show abstract